share_log

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal...

Benzinga ·  Sep 16 05:23

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal Carcinoma

  • Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel)
  • Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment